Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00584909 | A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus | terminated | Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00590967 | A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy | terminated | Phase 2 | 69 | Washington University School of MedicineOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02469116 | Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma | terminated | Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT01003938 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | terminated | Phase 2 | 45 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00671606 | Hysteroscopic Lymphatic Mapping for Endometrial Cancer | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 30 | Daniela Matei, MDOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00522301 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | terminated | Phase 2 | 34 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | terminated | Phase 2 | 8 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | terminated | Phase 2 | 6 | HaEmek Medical Center, IsraelOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00442598 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | terminated | Phase 2 | 17 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | terminated | Phase 2 | 24 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01747239 | Cabazitaxel in Platinum Refractory Ovarian Cancer | terminated | Phase 2 | 4 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00958893 | An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext | terminated | Phase 2 | 4 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 25, 2014 | clinicaltrials |
| NCT00470067 | Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer | terminated | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Aug 22, 2014 | clinicaltrials |
| NCT00683917 | Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 2 | 10 | Repros Therapeutics Inc.INDUSTRY | 2 | Aug 21, 2014 | clinicaltrials |
| NCT00626561 | Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00138151 | Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer | terminated | Phase 2 | 33 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Nov 20, 2013 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT01821859 | Abraxane/Bevacizumab | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00084448 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jul 9, 2013 | clinicaltrials |
| NCT00002478 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00003179 | Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer | terminated | Phase 2 | 360 | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00583622 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT01383408 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | terminated | Phase 2 | 752 | Schillerhoehe HospitalOTHER | 1 | May 7, 2013 | clinicaltrials |
| NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00004037 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006224 | Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006482 | Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006812 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00030472 | Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer | terminated | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2017source: clinicaltrials